Advancements are happening everyday

Treatment and research are intimately linked. The best treatments today may be upstaged by new therapies discovered in research in the future. Take your time to learn about treatment options currently available and new ones that are on the way. 

Advancements are happening everyday

Treatment and research are intimately linked. The best treatments today may be upstaged by new therapies discovered in research in the future. Take your time and learn about what treatment options are now available and the new ones are on the way. 

Treatment and Research: 4 Things to Know

CLL patients are living longer than ever.

The life expectancy of patients diagnosed with CLL/SLL has improved every decade, largely because of improved care made possible by new treatments and research.

CLL treatments are better than ever.

In almost every setting and in almost every subgroup studied, the newer targeted therapies approved since 2015 have proven superior to older protocols using chemotherapy.

Better single agents and drug combinations show promise.

New improved medications and drug combinations are constantly improving outcomes.

Research drives success.

CLL/SLL is not a solved problem and never will be without new treatments and more research.

CLL patients are living longer than ever.

The life expectancy of patients diagnosed with CLL/SLL has improved every decade, largely because of improved care made possible by new treatments and research.

CLL treatments are better than ever.

In almost every setting and in almost every subgroup studied, the newer targeted therapies approved since 2015 have proven superior to older protocols using chemotherapy.

Better single agents and drug combinations show promise.

New improved medications and drug combinations are constantly improving outcomes.

Research drives success.

CLL/SLL is not a solved problem and never will be without new treatments and more research.

FEATURE

ASH 2022: Dr. Jennifer Brown on Zanubrutinib vs. Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL/SLL)


The Bottom Line:

Zanubrutinib is more efficacious than ibrutinib and produces longer progression-free survival (PFS) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). It is also better tolerated with fewer cardiac side effects than ibrutinib.

Who Performed the Research and Where Was it Presented:

Dr. Jennifer Brown from Dana-Farber Cancer Institute and colleagues presented the results at the American Society for Hematology Annual Meeting in 2022 and a companion article published in the New England Journal of Medicine (NEJM).

Read More.

ADDITIONAL READING

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with
In this interview, Dr. Brian Koffman interviewed Dr. Jennifer Brown, Director of the CLL Center at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. They discussed the ALPINE trial, a phase 3 clinical trial directly comparing the efficacy of zanubrutinib vs. ibrutinib in patients with relapsed/refractory